drugset
Drugs / inactivated SARS-CoV-2 vaccine (Vero Cells)
last change Dec 2022 re-read 3 minutes ago

inactivated SARS-CoV-2 vaccine (Vero Cells)

Vaccine

Developed for
pneumonia
Investigated by
Center for Disease Control and Prevention, Fujian · China National Biotec Group Company Limited · Guizhou Center for Disease Control and Prevention · Hunan Provincial Center for Disease Control and Prevention · Wuhan Institute of Biological Products Co., Ltd

Trials 1

today NCT05104437 · Ph 4
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT05104437 Nov 2021 → Nov 2022 pneumonia China National Biotec Group Company Limited Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as inactivated SARS-CoV-2 vaccine (Vero Cells) “A Post-marketing Clinical Study of a Third Dose of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Wuhan): Immunogenicity, Safety and Antibody Persistence...” NCT05104437 ↗
Modality Vaccine “third dose of the inactivated SARS-CoV-2 vaccine (Vero cells)” NCT05104437 ↗